Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)

NCT ID: NCT01113502

Last Updated: 2021-08-05

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-06-30
• Study Completion Date: 2015-11-10

Brief Summary

This is a phase I/II open label study being conducted to evaluate the overall safety and initial effectiveness of an investigational drug, Eltrombopag in patients who are 60 years of age and older and who have Acute Myelogenous Leukemia (AML). Eltrombopag is an investigational drug, which means it has not been approved by the U.S. Food and Drug Administration (FDA) for use in this type of disease. Approximately 35 people will be enrolled on this study at the University of Pennsylvania

Detailed Description

Primary Objectives (Phase I Portion): 1). To determine the safety and tolerability of eltrombopag in elderly subjects with AML 2). To determine the maximally tolerated initial starting dose of eltrombopag for elderly subjects with AML Primary Objectives (Phase II portion): 1). To better define the safety and tolerability of eltrombopag in elderly patients with AML at the maximally tolerated starting dose Page 9 of 18 determined in Phase I portion of study. 2). To determine the incidence of peripheral platelet count improvement (using baseline and response parameters as defined below) for subjects with disease related thrombocytopenia. Secondary Objectives (Phase I and II): 1). To preliminarily determine the efficacy (using AML response criteria as defined below) of eltrombopag in elderly subjects with AML.

2). To perform ex-vivo analyses using subject AML samples and stock eltrombopag to 1) assess leukemic proliferative capacity and 2) investigate potential eltrombopag induced cytoxic mechanisms for leukemic cell death. 3). To perform pharmacodynamic assessments of drug activity in leukemic cells using subject samples collected at various time points before and during drug exposure. 4). To preliminarily correlate pharmacodynamic findings with clinical response.

Conditions

Acute Myelogenous Leukemia (AML)

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Phase 1 DL1

50 mg; Taken daily by mouth

Group Type: EXPERIMENTAL

Eltrombopag

Intervention Type: DRUG

Oral formulation taken daily

Phase 1 DL 2

100 mg; Taken daily by mouth

Group Type: EXPERIMENTAL

Eltrombopag

Intervention Type: DRUG

Oral formulation taken daily

Phase 1 DL3

200 mg; Taken daily by mouth

Group Type: EXPERIMENTAL

Eltrombopag

Intervention Type: DRUG

Oral formulation taken daily

Phase 1 DL 4

300 mg; Taken daily by mouth

Group Type: EXPERIMENTAL

Eltrombopag

Intervention Type: DRUG

Oral formulation taken daily

Phase 2

200 mg taken daily by mouth for 2 weeks; then 300 mg taken daily by mouth

Group Type: EXPERIMENTAL

Eltrombopag

Intervention Type: DRUG

Oral formulation taken daily

Interventions

Eltrombopag

Oral formulation taken daily

Intervention Type: DRUG

Other Intervention Names

SB-497115-GR

Eligibility Criteria

Inclusion Criteria

• A diagnosis of non-M3 AML which is either: a). Relapsed after standard chemotherapy or transplant;
• Newly diagnosed in a patient who is not an appropriate or willing candidate for standard induction chemotherapy - Age equal to or greater than 60 - Platelet count less than 75 - ECOG performance status of 0-2
• Life expectancy of at least 4 weeks
• Must be able to consume oral medication
• Must have recovered from toxic effects of prior chemotherapy
• Patients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.
• For Phase I portion only: Subject must be of non-East Asian (Japanese, Chinese, Taiwanese or Korean) descent.
• For Phase II portion subject can be either East Asian or non-East Asian descent.

Exclusion Criteria

• Cytotoxic chemotherapy (including azacitidine or decitabine) within the past 28 days other than hydroxyurea
• Active participation in any other investigational treatment study for AML.
• Known HIV or Hepatitis C
• ECOG performance status greater than 2
• Uncontrolled intercurrent illness including, but not limited to: uncontrolled ongoing infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Previous therapy with romiplostim or any other TPO-R agonist

• Minimum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abramson Cancer Center at Penn Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Noelle Frey, MD

Role: PRINCIPAL_INVESTIGATOR

Abramson Cancer Center at Penn Medicine

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Countries

United States

Other Identifiers

UPCC 17409

Identifier Type: -

Identifier Source: org_study_id